Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.
David Jiménez,Aldara García-Sánchez,Parth Rali,Alfonso Muriel,Behnood Bikdeli,Behnood Bikdeli,Pedro Ruiz-Artacho,Raphael Le Mao,Carmen Rodriguez,Beverley J. Hunt,Manuel Monreal +10 more
TLDR
A systematic review and meta-analysis of 15 standard and COVID-19 specific sources found the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT and subsegmental PE, in critically ill patients, and in prospective studies.About:
This article is published in Chest.The article was published on 2021-03-01 and is currently open access. It has received 347 citations till now. The article focuses on the topics: Incidence (epidemiology).read more
Citations
More filters
Journal ArticleDOI
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby,Marion K Campbell,Enti Spata,Jonathan Emberson,Natalie Staplin,Guilherme Pessoa-Amorim,Leon Peto,Martin Wiselka,L Wiffen,Simon Tiberi,B Caplin,C Wroe,Carole Green,Paul Hine,B Prudon,T George,A Wight,J K Baillie,Buddha Basnyat,Maya H Buch,Lucy C Chappell,Jeremy N. Day,Saul N. Faust,Raph L. Hamers,Thomas Jaki,Edmund Juszczak,Katie Jeffery,Wei Shen Lim,Alan A Montgomery,Andrew D Mumford,Kathy Rowan,G Thwaites,M Mafham,Richard Haynes,Martin J Landray +34 more
TL;DR: In this paper, the authors evaluated the effects ofcilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation, and found that the drug improved survival and other clinical outcomes.
Journal ArticleDOI
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
Inspiration Investigators,Parham Sadeghipour,Azita Hajhossein Talasaz,Farid Rashidi,Babak Sharif-Kashani,Mohammad Taghi Beigmohammadi,Mohsen Farrokhpour,Seyed Hashem Sezavar,Pooya Payandemehr,Ali Dabbagh,Keivan Gohari Moghadam,Sepehr Jamalkhani,Hossein Khalili,Mahdi Yadollahzadeh,Taghi Riahi,Parisa Rezaeifar,Ouria Tahamtan,Samira Matin,Atefeh Abedini,Somayeh Lookzadeh,Hamid Reza Rahmani,Elnaz Zoghi,Keyhan Mohammadi,Pardis Sadeghipour,Homa Abri,Sanaz Hariri Tabrizi,Seyed Masoud Mousavian,Shaghayegh Shahmirzaei,Hooman Bakhshandeh,Ahmad Amin,Farnaz Rafiee,Elahe Baghizadeh,Bahram Mohebbi,Seyed Ehsan Parhizgar,Rasoul Aliannejad,Vahid Eslami,Alireza Kashefizadeh,Hessam Kakavand,Seyed Hossein Hosseini,Shadi Shafaghi,Samrand Fattah Ghazi,Atabak Najafi,David Jiménez,Aakriti Gupta,Aakriti Gupta,Mahesh V. Madhavan,Sanjum S. Sethi,Sahil A. Parikh,Manuel Monreal,Naser Hadavand,Alireza Hajighasemi,Majid Maleki,Saeed Sadeghian,Gregory Piazza,Ajay J. Kirtane,Benjamin W. Van Tassell,Paul P. Dobesh,Gregg W. Stone,Gregory Y.H. Lip,Gregory Y.H. Lip,Harlan M. Krumholz,Samuel Z. Goldhaber,Behnood Bikdeli,Behnood Bikdeli +63 more
TL;DR: In this paper, the authors evaluated the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).
Journal ArticleDOI
Symptoms, complications and management of long COVID: a review.
Olalekan Lee Aiyegbusi,Sarah E. Hughes,Sarah E. Hughes,Grace M Turner,Samantha Cruz Rivera,Christel McMullan,Joht Singh Chandan,Shamil Haroon,Gary Price,Elin Haf Davies,Krishnarajah Nirantharakumar,Elizabeth Sapey,Melanie Calvert +12 more
TL;DR: The most prevalent reported symptoms were fatigue, shortness of breath, muscle pain, joint pain, headache, cough, chest pain, altered smell, altered taste and diarrhoea.
Journal ArticleDOI
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Bruna Bronhara,Lucas P. Damiani,Lilian Mazza Barbosa,Júlia de Aveiro Morata,Eduardo Ramacciotti,Priscilla de Aquino Martins,Aryadne Lyrio de Oliveira,Vinicius Santana Nunes,Luiz Eduardo Fonteles Ritt,Ana Thereza Rocha,Lucas Tramujas,Sueli V Santos,Dario Rafael Abregu Diaz,Lorena Souza Viana,Livia Maria Garcia Melro,Mariana Silveira de Alcântara Chaud,Estêvão Lanna Figueiredo,Fernando Carvalho Neuenschwander,Marianna Deway Andrade Dracoulakis,Rodolfo Godinho Souza Dourado Lima,Vicente C.S. Dantas,Anne Cristine Silva Fernandes,Otavio Gebara,Mauro E. Hernandes,Diego Aparecido Rios Queiroz,Viviane C Veiga,Manoel Fernandes Canesin,Leonardo Meira de Faria,Gilson Soares Feitosa-Filho,Marcelo Basso Gazzana,Idelzuíta Leandro Liporace,Aline de Oliveira Twardowsky,Lilia Nigro Maia,Flávia Ribeiro Machado,Alexandre de Matos Soeiro,Germano Emílio Conceição-Souza,Luciana Armaganijan,Patrícia O. Guimarães,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,John H. Alexander,Alvaro Avezum,Alexandre Biasi Cavalcanti,Otavio Berwanger +47 more
TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed
Journal ArticleDOI
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
TL;DR: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties as discussed by the authors , and a 1:1 ratio to either usual standard care plus 150 mg aspirin once per day until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
Meta-analysis of observational studies in epidemiology - A proposal for reporting
Donna F. Stroup,Jesse A. Berlin,Sally C. Morton,Ingram Olkin,G. D. Williamson,Drummond Rennie,Drummond Rennie,David Moher,Betsy Jane Becker,Theresa Ann Sipe,Stephen B. Thacker +10 more
TL;DR: A checklist contains specifications for reporting of meta-analyses of observational studies in epidemiology, including background, search strategy, methods, results, discussion, and conclusion should improve the usefulness ofMeta-an analyses for authors, reviewers, editors, readers, and decision makers.
The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
TL;DR: The Newcastle-Ottawa Scale (NOS) as discussed by the authors was developed to assess the quality of nonrandomised studies with its design, content and ease of use directed to the task of incorporating the quality assessments in the interpretation of meta-analytic results.
Journal ArticleDOI
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
TL;DR: In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronvirus pneumonia (NCP) cases were a concern.
Related Papers (5)
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Julie Helms,Charles Tacquard,François Severac,Ian Leonard-Lorant,Mickaël Ohana,Xavier Delabranche,Hamid Merdji,Raphaël Clere-Jehl,Malika Schenck,Florence Fagot Gandet,Samira Fafi-Kremer,Vincent Castelain,Francis Schneider,Lelia Grunebaum,Eduardo Anglés-Cano,Laurent Sattler,Paul-Michel Mertes,Ferhat Meziani +17 more
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more